HSINCHU, Taiwan, April 07, 2016 -- SemiLEDs Corporation (NASDAQ:LEDS), will report financial results for the 2016 fiscal second quarter ended February 29, 2016 and outlook for the fiscal third quarter after market close on Tuesday, April 12, 2016.
About SemiLEDs
SemiLEDs develops and manufactures LED chips and LED components primarily for general lighting applications, including street lights and commercial, industrial and residential lighting, along with specialty industrial applications such as ultraviolet (UV) curing, medical/cosmetic, counterfeit detection, horticulture, architectural lighting and entertainment lighting. SemiLEDs sells blue, white, green and UV LED chips.
Christopher Lee Chief Financial Officer +886-37-586788 [email protected]


Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S.
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 



